Side-by-side · Research reference

AHK-CuvsPinealon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED14/43 cited

BHuman-MechanisticAUTO-DRAFTED12/36 cited

AHK-Cu

Tripeptide-Copper Complex · Cosmetic

10⁻¹² – 10⁻⁹ MActive range (in vitro)Pyo 2007

Dermal papilla cellsPrimary targetPyo 2007

TopicalRoute

Topical · Scalp / Skin

Pinealon

Pineal-derived · Neuroprotective

5–10 mgPer cycle doseKhavinson 2014

HumanMechanisticKhavinson 2014

HoursHalf-life (est)

SQ or IM · Daily for 10 days · 1-2×/year

01Mechanism of Action

Parameter

AHK-Cu

Pinealon

Primary target

Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007

Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014

Pathway

AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007

Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014

Downstream effect

Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007

Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014

Feedback intact?

—

Origin

Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu

Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014

Antibody development

—

02Dosage Protocols

Parameter

AHK-Cu

Pinealon

Effective concentration (in vitro)

10⁻¹² – 10⁻⁹ MPyo 2007

Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.

—

Topical formulation

0.001–0.01% (estimated cosmetic range)

No standardized human protocol published — extrapolated from in vitro data.

—

Frequency

Once or twice daily (topical application)

Once daily during cycle

Route

Topical — scalp or dermal application

—

Evidence basis

Ex vivo hair follicle / in vitro DPC studiesPyo 2007

Russian clinical trials + in vitroKhavinson 2014

Duration

Not established — cosmetic protocols typically 8–12 weeks

10-day cycles, 1–2× per year

Standard dose

—

5–10 mg / day for 10 daysKhavinson 2014

Lower / starter dose

—

2.5 mg / day

Reconstitution

—

Bacteriostatic water

Timing

—

No specific time

Half-life

—

Hours

04Side Effects & Safety

Parameter

AHK-Cu

Pinealon

Local irritation

Mild erythema, pruritus at application site (copper peptide class effect)

—

Copper sensitivity

Rare hypersensitivity reaction in copper-sensitive individuals

—

Systemic absorption

Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses

—

Data limitations

No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)

—

Injection site reaction

—

Mild irritation

Long-term safety

—

Limited Western data

Pregnancy / OB

—

Avoid

Absolute Contraindications

AHK-Cu

·Known copper allergy or Wilson's disease

Pinealon

·Pregnancy / breastfeeding

Relative Contraindications

AHK-Cu

·Broken or inflamed skin (increased absorption risk)
·Concurrent use of other copper-containing formulations

Pinealon

·Active malignancy (theoretical via gene expression modulation)

05Administration Protocol

Parameter

AHK-Cu

Pinealon

1. Topical application

Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.

Add 1–2 mL bacteriostatic water to 10 mg vial.

2. Frequency

Once or twice daily. Evening application preferred for overnight contact time.

SQ — abdomen preferred.

3. Scalp preparation

For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.

Daily during cycle, any time.

4. Storage

Room temperature, protected from light. Copper complexes may degrade in UV exposure.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Duration

Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

AHK-Cu

+ GHK-Cu

Moderate

View GHK-Cu →

Both tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.

AHK-Cu: 0.001–0.01% topical · AM
GHK-Cu: 0.001–0.01% topical · PM
Frequency: Daily alternation or combined formulation
Primary benefit: Comprehensive dermal regeneration, angiogenesis, hair follicle support

Pinealon

+ Epitalon

Moderate

View Epitalon →

Pinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.

Pinealon: 5–10 mg SQ · daily × 10 days
Epitalon: 5–10 mg SQ · daily × 10 days (overlap or alternate)
Primary benefit: Neuroprotection + telomere preservation

Khavinson 2014 Khavinson 2003